ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -26 مورد

Peroxisomal disorders

Peroxisomal disorders
Authors:
Ronald JA Wanders, PhD
Nancy Braverman, MD, MS
Section Editor:
Helen V Firth, DM, FRCP, FMedSci
Deputy Editor:
Jessica Kremen, MD
Literature review current through: Apr 2025. | This topic last updated: Sep 24, 2024.

INTRODUCTION — 

Peroxisomal disorders are a heterogeneous group of inborn errors of metabolism caused by impairment in the biogenesis of peroxisomes or one of their metabolic functions. In most cases, this results in neurologic dysfunction of varying extent.

The major peroxisomal disorders will be reviewed here. The most common peroxisomal disorder, X-linked adrenoleukodystrophy, is discussed in detail separately. (See "Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy".)

CLASSIFICATION — 

Various classification schemas have been proposed for peroxisomal disorders. In general, they can be classified according to the pathologic mechanism or the clinical characteristics.

Classification by mechanism — Peroxisomal disorders are divided into two major categories depending upon whether the defect is in the biogenesis of peroxisomes or a single peroxisomal enzyme deficiency (table 1) [1,2]. More recently, a third category has been described (disorders of peroxisome division); however, disorders in this category are exceedingly rare [3].

Peroxisome biogenesis disorders (PBD) – The PBD group is subdivided into two distinct subgroups including:

Zellweger spectrum disorders (ZSD) – In ZSD, there is a generalized loss of peroxisomal functions [4]. (See 'Zellweger spectrum disorders' below.)

Rhizomelic chondrodysplasia punctata (RCDP) types 1 and 5 – In these disorders, peroxisomes are present, but they lack a specific group of proteins. (See 'RCDP spectrum disorders' below.)

Single peroxisomal enzyme/protein disorders – The following disorders are characterized by deficiency (or upregulation) of a single peroxisomal enzyme or protein; peroxisome biogenesis is intact in these disorders:

ACBD5 (acyl-CoA-binding domain type 5) deficiency (MIM #618863)

ACOX1 (acyl CoA oxidase-1) deficiency (see 'ACOX1 and DBP deficiencies' below)

ACOX1 upregulation (Mitchell syndrome, MIM #618960)

ACOX2 deficiency (MIM #617308)

AMACR (alpha-methylacyl-CoA racemase) deficiency (see 'Other disorders' below)

BAAT (bile acid-CoA: amino acid N-acyltransferase) deficiency (see 'Other disorders' below)

DBP (D-bifunctional protein) deficiency (see 'ACOX1 and DBP deficiencies' below)

Glycolate oxidase deficiency

PMP70 (peroxisomal membrane protein 70) deficiency (MIM #616278)

Primary hyperoxaluria type 1 (alanine glyoxylate aminotransferase deficiency) (see "Primary hyperoxaluria", section on 'Primary hyperoxaluria type 1')

RCDP types 2, 3, and 4 (see 'RCDP spectrum disorders' below)

FAR1 (fatty acid acyl CoA reductase 1) upregulation (CSPSD disorder [cataracts, spastic paraparesis, and speech delay]; MIM #619338)

Refsum disease (phytanoyl-CoA hydroxylase deficiency)

SCPX (sterol carrier protein X) deficiency (MIM #613724)

X-linked adrenoleukodystrophy (X-ALD) (see "Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy")

Disorders of peroxisome division – These are rare disorders caused by mutations in genes encoding proteins involved in peroxisome division (eg, PEX11 beta, DLP1/DNML1, MFF, GDAP1) [3]. Some classification schemas characterize PEX11 beta deficiency as a PBD [5].

Clinical classification — Clinically, the peroxisomal disorders can be subdivided into six main groups, including (table 2):

Cerebrohepatorenal syndromes – This category includes disorders that are characterized by variable degrees of liver and kidney involvement in conjunction with neurologic abnormalities, vision and hearing impairment, and craniofacial dysmorphisms. These include:

Zellweger spectrum disorders (see 'Zellweger spectrum disorders' below)

ACOX1 deficiency (see 'ACOX1 and DBP deficiencies' below)

DBP deficiency (see 'ACOX1 and DBP deficiencies' below)

Rhizomelic chondrodysplasias – This category includes RCDP types 1 to 5. The unique feature that distinguishes RCDPs from other peroxisomal disorders is pronounced short stature that primarily affects the proximal long bones (rhizomelia). Other clinical features include developmental delay, dysmorphic facies, congenital cataracts, ichthyosis, and joint contractures. (See 'RCDP spectrum disorders' below.)

Refsum disease – Refsum disease is characterized by progressive vision loss and peripheral neuropathy. Unlike many other peroxisomal disorders, which often present in infancy or early childhood, Refsum disease typically presents in adolescence or early adulthood. (See 'Refsum disease' below.)

X-ALD – The clinical spectrum of X-ALD is variable, as summarized in the table (table 3) and discussed in detail separately. (See "Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy", section on 'Clinical features'.)

Primary hyperoxaluria type 1 (PH1) – PH1 is characterized by recurrent kidney stones and chronic kidney disease. It is discussed in detail separately. (See "Primary hyperoxaluria", section on 'Primary hyperoxaluria type 1'.)

Other rare disorders – The sixth category consists of a group of rare disorders with variable features. Some of these disorders are newly recognized and the full spectrum of disease is still emerging. These include (see 'Other disorders' below):

ACBD5 deficiency

ACOX1 upregulation

ACOX2 deficiency

AMACR deficiency

BAAT deficiency

FAR1 upregulation

SCPX deficiency

PMP70 deficiency

Glycolate oxidase deficiency

Disorders of peroxisome division

EPIDEMIOLOGY — 

Peroxisomal disorders occur in approximately 1 to 5 per 10,000 live births [2]. In one study, among 1000 patients with inborn errors of metabolism referred to a tertiary center between 1982 and 1997, peroxisomal disorders accounted for 3 percent [6].

X-linked adrenoleukodystrophy (X-ALD) is the most common peroxisomal disorder and is discussed separately. (See "Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy", section on 'Epidemiology'.)

Zellweger spectrum disorder (ZSD) is the most common peroxisomal disorder presenting in early infancy, with an estimated incidence of 1 to 4 per 100,000 live births [7].

PATHOPHYSIOLOGY — 

Peroxisomes are subcellular organelles with a variable diameter ranging from 0.05 to 0.5 micron in diameter and are present in all cells except erythrocytes. The highest concentration of peroxisomes is in the liver and kidney [8]. Although long regarded as organelles of little physiologic significance, peroxisomes are now known to catalyze a number of different functions in cellular metabolism, which include the following [9-11]:

Catalytic functions:

Beta-oxidation of very long chain fatty acids (VLCFA), pristanic acid, and long-chain dicarboxylic acids

Alpha-oxidation of phytanic acid

Oxidation of pipecolic acid

Detoxification of glyoxylate

Degradation of hydrogen peroxide by catalase

Anabolic functions:

Synthesis of primary bile acids

Synthesis of plasmalogens, which are important components of cell membranes and myelin

Synthesis of certain polyunsaturated fatty acids (PUFAs), notably docosahexaenoic acid (C22:6).

The pathophysiology of the different peroxisomal disorders is complex:

Zellweger spectrum disorder (ZSD) – In ZSD, there is a generalized loss of peroxisomal functions, caused by molecular defects in various peroxisome biogenesis (PEX) genes encoding PEX proteins or peroxins, which are proteins required for the proper biogenesis and maintenance of peroxisomes [4]. These defects interfere with the formation of pre-peroxisomal vesicles at the site of the endoplasmic reticulum and mitochondria, subsequent import of peroxisomal proteins into vesicles, and/or maintenance of peroxisomes [4]. (See 'Zellweger spectrum disorders' below.)

Rhizomelic chondrodysplasia punctata (RCDP) type 1 – In RCDP type 1, peroxisomes are present, but they lack a specific group of proteins due to mutations in one of the PEX genes (most commonly PEX7) [12]. This affects one of the two major import pathways for peroxisomal proteins into peroxisomes (ie, the PTS2-import pathway). As a consequence, several peroxisomal enzymes targeted to peroxisomes via the PTS2-pathway are deficient. The result is impaired synthesis of ether phospholipids (plasmalogens) and impaired alpha-oxidation of phytanic acid. (See 'RCDP spectrum disorders' below.)

Refsum disease – Accumulation of phytanic acid is the sole biochemical abnormality responsible for the physiologic consequences of Refsum disease. Phytanic acid is a branched-chain fatty acid derived from the chlorophyll constituent phytol that is present in the typical human diet. Normally, phytanic acid is metabolized by activation to its CoA ester, phytanoyl-CoA, and then metabolized via alpha-oxidation to pristanic acid. Patients with Refsum disease are unable to degrade phytanic acid because of deficient activity of phytanoyl-CoA hydroxylase (PHYH), a peroxisomal enzyme that catalyzes the first step of phytanic acid alpha-oxidation. The mechanism by which phytanic acid is toxic to neuronal and other tissues is uncertain. (See 'Refsum disease' below.)

ACOX2 and AMACR deficiencies – In Acyl-CoA oxidase 2 (ACOX2) and alpha-methylacyl-CoA racemase (AMACR) deficiencies, bile acid synthesis is impaired. The resulting accumulation of bile acids intermediates cause early-onset liver disease as the dominant feature. Patients with AMACR deficiency also accumulate pristanic acid and may develop late-onset progressive neurologic disease. (See 'Other disorders' below.)

NEUROPATHOLOGY — 

Mounting evidence implicates secondary mitochondrial dysfunction as a potential trigger of both neurodevelopmental defects and neurodegeneration [13]. Accumulation of alpha-synuclein oligomers, cell signaling abnormalities and inflammation have been suggested as additional disease mechanism [13]. Functional peroxisomes are also required for the maintenance of myelin [14].

The neuropathology of peroxisomal disorders is characterized by one or more of the following processes:

Migration and differentiation defects – Abnormal neuronal migration and differentiation vary in severity among the different disorders [15]. Migration of all neuronal classes appears to be affected, especially those destined for the outer layers of cortex.

The abnormalities are most prominent in Zellweger spectrum disorder (ZSD) and ZSD-like disorders, including D-bifunctional protein (DBP) deficiency. Severe ZSD and DBP are characterized by a unique combination of centrosylvian pachygyria-polymicrogyria likely responsible for seizures and global developmental delay seen in these patients [16]. In intermediate ZSD (previously classified as neonatal adrenoleukodystrophy), there are either no or less severe defects in cerebral migration. Polymicrogyria in these patients occurs as diffuse, focal, or multifocal lesions that may be associated with subcortical heterotopias [17]. These also occur in DBP deficiency [18,19]. More subtle neuronal migration defects appear as heterotopic Purkinje cells [20,21]. These are usually asymptomatic.

Neuronal migration abnormalities do not occur in all patients with peroxisomal disorders. Patients with mild ZSD do not typically have migration abnormalities and none have been identified in classic Refsum disease, acyl-CoA oxidase deficiency (pseudo-NALD), or X-linked adrenoleukodystrophy (X-ALD). They occur rarely in rhizomelic chondrodysplasia punctata (RCDP) [22].

Myelination abnormalities – Abnormalities in the formation or maintenance of central white matter and/or peripheral nerve myelin are frequently found in patients affected by peroxisomal disorders with neurologic involvement. Peripheral nerve involvement is less well studied than central lesions. An exception is Refsum disease, which typically has a hypertrophic (onion bulb) demyelinating neuropathy.

Degenerative central white matter lesions consist of myelin abnormalities that can be inflammatory [23,24] or noninflammatory, and nonspecific decreases in myelin volume or staining [25]. The latter can occur with or without reactive astrocytosis. The type of neuronal degeneration varies among the disorders:

Inflammatory demyelination – Inflammatory demyelination typically occurs in X-ALD. This is discussed in detail separately. (See "Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy", section on 'Neuropathology'.)

Other conditions in which inflammatory demyelination lesions occur less frequently include ZSD [17], and some cases of DBP deficiency.

Noninflammatory dysmyelination – Noninflammatory dysmyelination is seen in the early stages of adrenomyeloneuropathy (AMN). The myelin appears pale, with scant interstitial macrophages that stain positive with periodic acid Schiff (PAS). No lymphocytes or reactive astrocytes are seen.

Other changes in myelin – Other changes in myelin include nonspecific reductions in volume or staining, with or without reactive astrocytes.

Major post-developmental noninflammatory abnormalities may occur in specific neurons or myelinated fiber tracts. These may affect specialized sensory neurons, resulting in sensorineural hearing loss (in ZSD, DBP deficiency, ACOX1 deficiency and Refsum disease) or retinal pigmentary degeneration (in ZSD, Refsum disease and AMACR deficiency). In another lesion of this type, neurons of the dorsal nuclei of Clarke and the lateral cuneate nuclei accumulate lamellar lipids that contain VLCFA. This lesion occurs only in ZWS.

In AMN, a degenerative axonopathy involves the ascending and descending tracts of the spinal cord, especially in fasciculus gracilis and the lateral corticospinal tracts. The histologic pattern is Wallerian degeneration [26]. Mitochondrial pathology [27] and oxidative stress [28] also contribute to pathogenesis.

Cerebellar atrophy occurs in RCDP type 1 and ZSD. This appears to result from loss of Purkinje and granule cells, with focal depletion of basket cells.

CLINICAL SUSPICION OF PEROXISOMAL DISORDERS

Common clinical features — The clinical spectrum of peroxisomal disorders is broad, ranging from severe neurologic disability presenting in the neonatal period to minor symptoms manifesting in adulthood. Despite these phenotypic variabilities, there are recognizable patterns in clinical presentation suggestive of a peroxisomal disorder.

Common clinical features that should prompt consideration of a peroxisomal disorder include [6,29-31]:

Central and peripheral nervous system findings – Patients can present with variable degrees of developmental delay or cognitive impairment. Neurological examination may reveal signs of ataxia, myelopathy, and/or peripheral neuropathy.

Vision problems, retinopathy, cataracts, and other eye problems.

Sensorineural hearing loss.

Liver disease.

Adrenal insufficiency.

Skeletal abnormalities, such as growth failure primarily affecting the proximal long bones (rhizomelia) and calcific stippling on bone radiographs (chondrodysplasia punctata).

Diagnostic approach

No one-size-fits-all approach to testing — In general, when a peroxisomal disorder is suspected clinically, testing begins with measurement of specific biochemical markers related to the suspected disorder(s). There is no singular approach to the diagnosis of peroxisomal disorders since the choice of initial laboratory test(s) depends upon the constellation of clinical findings. Indeed, the long-held practice of measuring plasma very long-chain fatty acid (VLCFA) levels as an initial screening test to assess for peroxisomal disorders is not advised since VLCFAs are abnormal in only a subset of peroxisomal disorders (specifically, Zellweger spectrum disorders [ZSD], D-bifunctional protein [DBP] deficiency, acyl-CoA oxidase-1 [ACOX1] deficiency, and X-linked adrenoleukodystrophy [X-ALD]). While these represent the most common disorders, there are numerous other peroxisomal disorders that are now recognized that are not associated with elevated plasma VLCFAs.

Testing should be tailored to the specific disorder(s) suspected based upon the constellation of clinical findings (table 2) [32]:

Suspected ZSD (or ACOX1 or DBP deficiency, which are clinically indistinguishable) – Initial testing consists of measuring plasma C26:0-lysophosphatidylcholine (C26:0-LPC), if available. If C26:0-LPC is not available, standard VLCFA analysis is acceptable. (See 'Diagnosis' below.)

Suspected rhizomelic chondrodysplasia punctata (RCDP) disorders – Initial testing consists of erythrocyte plasmalogen analysis. (See 'Diagnosis' below.)

Suspected Refsum disease – Initial testing consists of plasma phytanic acid levels. (See 'Diagnosis' below.)

Suspected X-ALD – Initial testing consists of measuring plasma C26:0-LPC or VLCFA levels (table 3). Laboratory testing for X-ALD is discussed in detail separately. (See "Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy", section on 'Laboratory testing'.)

Primary hyperoxaluria type 1 (PH1) – Initial testing consists of measuring urinary oxalate. Laboratory testing for PH1 is discussed in detail separately. (See "Primary hyperoxaluria", section on 'Metabolic testing'.)

If results of initial biochemical tests are abnormal, confirmatory genetic testing is generally required. Gene panels are available that simultaneously test for multiple genetic variants that cause peroxisomal disorders. Information on genetic testing, including a list of accepted laboratories providing this testing, is available through the genetic testing registry. Additional confirmatory testing with functional assays using fibroblasts can sometimes be useful in the diagnostic evaluation (eg, if genetic testing identifies a variant of uncertain significance) [33].

Prenatal diagnosis — Prenatal testing for peroxisomal disorders is available for subsequent pregnancies of individuals with affected children or other positive family history. Prenatal diagnostic methods have generally shifted from biochemical to molecular-based methods. Using assisted reproductive technology, preimplantation diagnosis can be achieved in embryos using multiple displacement amplification [34]. Issues related to preimplantation genetic testing are discussed in greater detail separately. (See "Preimplantation genetic testing".)

Antenatal diagnosis is sometimes made by ultrasonography. In one report, increased nuchal translucency and decreased fetal movements suggested the diagnosis of Zellweger syndrome in a fetus at risk [35]. The diagnosis was confirmed by metabolic studies on cells obtained by chorionic villus sampling. In another report, RCDP was identified in a fetus with no family history based on the findings of severe limb shortening, premature ossification, and stippling of multiple epiphyses [36].

Newborn screening — Newborn screening for X-ALD is discussed in a separate topic review. (See "Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy", section on 'Newborn screening'.)

The screening approach used for X-ALD, which involves measurement of VLCFAs, also detects other peroxisomal disorders, including ZSD.

Patients identified through next-generation sequencing — In contemporary practice, patients with peroxisomal disorders are often identified through next-generation sequencing methods, including whole genome or whole exome sequencing (WGS or WES). For example, a child with unexplained severe neurodevelopmental disability may undergo testing with WGS or WES, which may identify a variant associated with a peroxisomal disorder. (See "Inborn errors of metabolism: Identifying the specific disorder", section on 'Molecular genetic testing' and "Cerebral palsy: Evaluation and diagnosis", section on 'Metabolic and genetic testing' and "Intellectual disability (ID) in children: Evaluation for a cause", section on 'Whole exome or genome sequencing'.)

In most cases when a peroxisomal disorder is identified through WGS or WES, it is appropriate to perform confirmatory biochemical testing for the specific disorder, as discussed in the following sections [32].

SPECIFIC DISORDERS

Zellweger spectrum disorders — Zellweger syndrome (ZS; MIM #214100), also known as cerebrohepatorenal syndrome, is the prototype of the group of peroxisome biosynthesis disorders. It is a classic congenital malformation syndrome characterized by craniofacial dysmorphisms and profound neurologic abnormalities due to neuronal migration defects. It is now recognized that ZS represents the most severe presentation within a larger spectrum known as the Zellweger spectrum disorders (ZSD).

There is considerable variability within the literature regarding the classification of milder variants within the ZSD category. Some conditions included in this category were previously considered separate disorders. including neonatal adrenoleukodystrophy (NALD), infantile Refsum disease (IRD), and Heimler syndrome [37]. However, since they are all caused by defects in the same genes as ZSD (eg, PEX1 and PEX6) with a similar constellation of clinical and laboratory findings, they are now considered part of the Zellweger spectrum. The inclusive term ZSD recognizes the common etiology, the overlapping spectrum of phenotype severity, and allows for the incorporation of newly described phenotypes. As discussed below, D-bifunctional protein (DBP) deficiency and Acyl CoA oxidase-1 (ACOX1) deficiency are clinically indistinguishable from the ZSDs. (See 'ACOX1 and DBP deficiencies' below.)

Genetics

Genetic variants – ZSDs are caused by mutations in at least 14 different PEX genes which are inherited in an autosomal recessive pattern [38]. Variants in either the PEX1 or PEX6 genes account for approximately 75 percent of cases. PEX1 or PEX6 encode for ATPases that are required to import proteins from the cytosol into peroxisomes [39]. A minority of cases are caused by variants in other PEX genes [40-43].

Genotype-phenotype relationship – The genotype-phenotype relationship has best been established for common variants of the PEX1 gene [44,45]. Patients homozygous for the PEX1-p.Ile700fs variant have no PEX1 protein, which manifests as severe ZSD [46]. By contrast, patients homozygous for the PEX1-p.Gly843Asp variant retain residual protein function and are typically more mildly affected. Compound heterozygotes for these two variants exhibit intermediate ZSD phenotypes. As a general rule, individuals harboring two genetic variants in a PEX gene that predict complete loss of protein functions usually have severe ZSD, whereas individuals with a least one variant predicted to have residual protein function have an intermediate or milder ZSD phenotype. However, there are exceptions to this.

Clinical features — There are three general categories of ZSDs based upon the age at presentation:

Severe ZSD (classical infantile ZS) – Infants with classical ZS present in the newborn period with a severe phenotype characterized by a combination of characteristic findings, including [31,47,48]:

Craniofacial dysmorphisms, which may include (picture 1):

-High forehead

-Large anterior fontanelle

-Markedly separated cranial sutures

-Hypoplastic supraorbital ridges

-Upward slant of the eyes

-Epicanthal folds

-Low and broad nasal bridge

-High-arched palate

-Deformed ear lobes

Hepatomegaly with associated with cholestasis, cirrhosis, biliary dysgenesis, and coagulopathy

Neurologic abnormalities, including:

-Profound hypotonia and weakness with absent reflexes

-Severe hearing and vision impairment

-Neonatal seizures

-Profound global developmental delay

-Abnormalities on neuroimaging (see 'Neuroimaging findings' below)

Calcific stippling, typically of the patellae and hips (chondrodysplasia punctata), observed on skeletal x-ray, which is present in 50 to 70 percent of affected infants [49]

Cortical kidney cysts seen on abdominal imaging

Pigmentary retinopathy and cataracts [50] (see "Cataract in children")

Dental enamel defects (ameleogenesis imperfecta)

Infants with severe ZSD typically do not reach any developmental milestones and survival beyond the age of 12 months is rare [49].

Intermediate ZSD (childhood presentation) – The usual onset for this category is between the first and second year of life. The disease spectrum of the childhood form is more variable compared with severe ZSD, though there is some overlap:

Developmental delay – Children may first come to clinical attention because of delayed developmental milestones and/or hypotonia.

Vision and hearing impairment – Progressive bilateral visual impairment and sensorineural hearing loss are consistent features. Ocular abnormalities include pigmentary retinopathy, cataract, optic nerve atrophy, glaucoma, and Bushfield spots.

Liver disease – Liver dysfunction with hepatomegaly, portal hypertension, prolonged jaundice, and cholestasis are frequent findings.

Facial dysmorphism are usually more subtle compared with severe ZSD.

The prognosis is variable, depending on the constellation of findings; many patients do not survive to adulthood [31,51].

Mild ZSD – The phenotypic spectrum of mild ZSD is much broader, including patients with isolated hearing loss and vision problems or isolated cerebellar ataxia [52,53]. Patients with mild ZSD may present in childhood, adolescence, or adulthood. Sensorineural hearing loss, ocular abnormalities, and defects of dental enamel (ameleogenesis imperfecta) are important clues to the diagnosis of ZSD in these patients [7]. Craniofacial dysmorphisms tend to be subtle or completely absent. Cognitive function can range from normal to mild or moderate intellectual disability. Adrenal insufficiency is common although it is asymptomatic in >50 percent of affected patients [54].

Increasingly, patients with mild and intermediate ZSD are diagnosed at earlier ages when they are less symptomatic. This is due to increased awareness of ZSD, greater availability of next generation sequencing, and implementation of newborn screening for XALD, which also identifies infants with ZSD, DBP, or ACOX1 deficiency. (See "Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy", section on 'Newborn screening'.)

Neuroimaging findings — Findings on brain magnetic resonance imaging (MRI) include cortical and white matter abnormalities [55]. In a study of six infants with severe ZSD, all had impaired myelination and diffusely abnormal cortical gyral patterns, consisting of microgyria and pachygyria [56]. All had germinolytic cysts in the caudothalamic groove. In mildly affected patients, MRI abnormalities may be subtle or absent [57-59].

Diagnosis

Initial testing – When ZSD is clinically suspected, we suggest initial testing with a plasma C26:0-lysophosphatidylcholine (C26:0-LPC) level. C26:0-LPC is a more sensitive marker compared with the standard very long-chain fatty acid (VLCFA) parameters (which include C26:0 level, ratio of C26:0 to docosanoic acid [C26:0/C22:0], and ratio of C26:0 to tetracosanoic acid [C26:0/C24:0]) [60]. However, C26:0-LPC analysis is not available in all settings and standard VLCFA analysis is acceptable for initial testing if C26:0-LPC is not available.

Elevated plasma VLCFA levels, particularly C26:0-LPC, are suggestive of ZSD, DBP deficiency, or ACOX1 deficiency [61-65]. These levels are also elevated in patients with X-ALD, as discussed separately. (See "Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy", section on 'Very long-chain fatty acid levels'.)

VLCFA levels can occasionally be normal in patients with ZSD, particularly those who are older and/or mildly affected. In addition, abnormal VLCFA can be seen in patients without peroxisomal disorders who are on ketogenic diets and occasionally in those who have consumed large amounts of peanuts [66,67].

Further biochemical testing – If plasma C26:0-LPC or VLCFA analysis is abnormal, additional testing is performed in the same blood sample, including:

Analysis of peroxisomal biomarkers in plasma (C27 bile acid intermediates [dihydrocholestanoic acid and tryhydrocholestanoic acid], phytanic acid, pristanic acid, pipecolic acid)

Peroxisomal biomarkers in erythrocytes (plasmalogens)

Distinguishing between ZSD and DBP or ACOX1 deficiency – Analysis of this set of peroxisomal biomarkers usually allows discrimination between ZSDs and DBP or ACOX1 deficiency. In patients with ZSD, all peroxisomal biomarkers are abnormal whereas in patients with DBP or ACOX1 deficiency, erythrocyte plasmalogen levels are normal. ACOX1 deficiency can easily be distinguished from DBP deficiency because in ACOX1 deficiency, there is only accumulation of VLCFAs. By contrast, in DBP deficiency, there is accumulation of VLCFAs, bile acid intermediates, and pristanic and phytanic acid. A pitfall is that mildly affected patients may show a less uniform biochemical phenotype which may make it challenging to interpret the initial laboratory findings.

Confirming the diagnosis (genetic testing) – The combination of characteristic clinical features, abnormal VLCFA levels, and pattern of peroxisomal biomarkers in plasma and erythrocytes is sufficient to establish a preliminary diagnosis of ZSD. The diagnosis is confirmed with genetic testing. Genetic testing ensures certainty of the diagnosis and facilitates genetic counseling. Testing consists of sequencing analysis of the PEX genes. Gene panels are available that simultaneously test for multiple genetic variants that cause ZSD and other peroxisomal disorders (eg, PEX screen and others). Additional information on genetic testing, including a list of accepted laboratories providing this testing, is available through the genetic testing registry.

In some cases, additional functional studies in fibroblasts are needed to confirm the diagnosis [33]. This most commonly occurs when genetic testing identifies new mutations or variants of uncertain significance (VUS). Functional assays are performed in this setting to evaluate the biochemical significance of the variant.

Treatment — Treatment for patients with ZSD, DBP deficiency, or ACOX1 deficiency is supportive. There are no treatments that effectively correct the underlying metabolic pathophysiology or prevent or arrest neurologic and other consequences of the disease. Appropriate counseling and support should be provided for the family/caregivers.

Treatments that have been investigated include:

Docosahexaenoic acid (DHA) supplementation – Limited observational data suggest that DHA supplementation may improve some biochemical markers in patients with ZSD [68]; however, in a small randomized trial, DHA supplementation did not meaningfully improve clinical outcomes [69].

Cholic acid supplementation – A small uncontrolled study demonstrated that cholic acid supplementation reduced levels of toxic bile acid intermediates compared with pretreatment baseline levels in patients with ZSD [70]; however, after 21 months of treatment, there were no apparent improvements in any clinically relevant outcomes (eg, liver function, growth, survival) [71]. Nevertheless, cholic acid has been approved by the United States Food and Drug Administration for this indication [72]. It was also approved by the European Medicines Agency (EMA), but it was subsequently withdrawn from the European market [73].

ACOX1 and DBP deficiencies — The clinical signs and symptoms in patients with ACOX1 deficiency or DBP deficiency are indistinguishable from those of patients with ZSD [74,75]. Indeed, the first reported cases of DBP deficiency were described as pseudo-Zellweger syndrome. (See 'Zellweger spectrum disorders' above.)

The similarities extend to neuroimaging findings, which include both developmental abnormalities (such as cortical dysplasia, peri-Sylvian polymicrogyria, delayed myelination, and germinolytic cysts) as well as late onset progressive lesions (decreasing white matter volume and bilateral ventricular dilatation and white matter lesions) [30]. (See 'Neuroimaging findings' above.)

Like ZSD, patients with DBP deficiency show a clinical spectrum of disease severity depending upon whether there is residual DBP activity. Findings in patients with mild disease may include hypogonadism (or ovarian dysgenesis), sensorineural hearing loss, variable cognitive impairment, cerebellar atrophy, and peripheral neuropathy [64].

The approach to diagnostic testing is the same as for ZSD (ie, plasma C26:0-LPC or VLCFA analysis is the initial test). Ultimately, these disorders are distinguished from ZSD on the basis of the pattern of peroxisomal biomarkers in plasma and erythrocytes and by molecular genetic testing, as discussed above. (See 'Diagnosis' above.)

RCDP spectrum disorders — Rhizomelic chondrodysplasia punctata (RCDP) type 1 (MIM #215100) is the prototype of this group of peroxisomal chondrodysplasias which now includes five distinct genetic forms.

Genetics — Five different genotypic variants of RCDP have been identified, all of which have an autosomal recessive inheritance pattern:

RCDP type 1 – RCDP type 1 is caused by variants in the PEX7 gene. This is the most common form of RCDP, accounting for 80 to 90 percent of cases [76-82]. PEX7 encodes the peroxisomal type 2 targeting signal receptor that helps target cytosolic proteins to the peroxisome. PEX7 variants can also cause Refsum disease [83]. (See 'Refsum disease' below.)

RCDP type 2 – RCDP type 2 is caused by variants in the gene that encodes glyceronephosphate O-acyltransferase (GNPAT).

RCDP type 3 – RCDP type 3 is caused by variants in the gene that encodes alkylglycerone phosphate synthase (AGPS).

RCDP type 4 – RCDP type 4 is caused by variants in the gene that encodes fatty acyl-CoA reductase 1 (FAR1) [84].

RCDP type 5 – RCDP type 5 is caused by variants in PEX5 that disrupt the protein domain of PEX5 that binds to PEX7 [85].

RCDP type 1 and 5 are classified as peroxisome biogenesis disorders since PEX7 and PEX5 genes encode proteins involved in the proper targeting of peroxisomal proteins to peroxisomes. RCDP types 2, 3, and 4, are single peroxisomal enzyme deficiencies. In all five types of RCDP, synthesis of ether phospholipid is defective, which leads to a deficiency of plasmalogens (the dominant ether phospholipid species in mammals) in all cell types, including erythrocytes.

Clinical features — Despite the variety in the molecular defects, RCDP types 1, 2, 3, and 5 are clinically indistinguishable. The clinical features of RCDP type 4 are somewhat distinct though there are few reported cases [84].

RCDPs present in early childhood with characteristic findings that include:

Short stature with rhizomelia – The unique feature that distinguishes RDCPs from other peroxisomal disorders is pronounced growth failure that primarily affects the proximal long bones (rhizomelia).

Global developmental delay, which can be profound.

Dysmorphic facies.

Congenital cataracts (present in nearly all patients).

Congenital heart disease (present in approximately 50 to 60 percent of patients)

Ichthyosis (present in approximately 25 percent of patients).

Joint contractures.

Seizures.

Patients with severe forms of RCDP are generally recognized shortly after birth with symmetrical rhizomelic shortening of the humerus and, to a lesser extent, the femurs and facial dysmorphisms. In patients with milder phenotypes, there may be only minor shortening of the proximal extremities with normal or near normal stature. Developmental delay can also be less severe [86].

Radiographic findings — The characteristic radiographic findings of RCDP are:

Rhizomelia, which refers to shortening of the proximal long bones. It typically affects the humerus more than the femurs.

Chondrodysplasia punctata, which refers to stippled epiphyseal calcification caused by premature mineralization. It can be seen in the long bones, vertebrae, and costochondral junctions.The stippling becomes less obvious radiographically over time, and there is appearance of metaphyseal splaying and abnormal ossification of long bones.

Other radiographics findings may include:

Lateral spine radiographs may demonstrate coronal clefts of the vertebral bodies, which is thought to represent delayed mineralization.

Cervical stenosis and thoracolumbar kyphoscoliosis (image 1).

Neuroimaging findings — Reported findings on brain MRI in patients with RDCPs include [87-89]:

White matter changes

Pachygyria and polymicrogyria

Ventriculomegaly

Increased subarachnoid spaces

Cerebellar atrophy

Children with more severe clinical disease are more likely to have abnormal MRI findings [89].

Even in the absence of white matter lesions on routine MRI, hydrogen-1 MR spectroscopy may demonstrate metabolic abnormalities consistent with the deficient plasmalogen biosynthesis [87].

Diagnosis — When RDCP is suspected clinically, we suggest initial testing with erythrocyte plasmalogen analysis. Plasma VLCFA analysis does not play a role in the diagnosis of RCDPs since VLCFA levels are not elevated in these disorders.

RCDPs of all types and severities are associated with low levels of plasmalogens, although the deficiency may be less pronounced in mildly affected patients [90]. In RCDP types 2, 3, and 4 the deficiency of plasmalogens is the only biochemical abnormality. Patients with RCDP types 1 and 5 typically also have elevated plasma phytanic acid levels, though these levels can be in the normal range, depending on dietary intake of phytanic acid.

The combination of characteristic clinical features and low levels of erythrocyte plasmalogens is sufficient to establish a preliminary diagnosis of RCDP. The diagnosis is confirmed with genetic testing. Genetic testing ensures certainty of the diagnosis and facilitates genetic counseling. Gene panels are available that simultaneously test for multiple genetic variants that cause RCDPs and other peroxisomal disorders [76,81]. Additional information on genetic testing, including a list of accepted laboratories providing this testing, is available through the genetic testing registry.

Treatment — Treatment for patients with RCDP is supportive and may include:

Antiseizure medication for patients with seizures (see "Seizures and epilepsy in children: Initial treatment and monitoring")

Treatment of cataracts (see "Cataract in children")

Physical therapy to prevent contractures (see "Cerebral palsy: Treatment of spasticity, dystonia, and associated orthopedic issues", section on 'Physical and occupational therapy')

All patients should have routine evaluations to identify cardiac and ocular abnormalities. Orthopedic issues should be managed in collaboration with a pediatric orthopedic specialist. Regular assessment of nutritional status should also be performed.

The available evidence suggests that restriction of phytanic acid intake does not alter the disease course in RCDP [82]. This is consistent with the primary disease etiology being plasmalogen deficiency. This is in contrast to Refsum disease, which responds to dietary intervention. (See 'Treatment' below.)

Prognosis — The prognosis for patients with RCDP, particularly RCDP type 1, is generally poor. In a report of 66 patients with RCDP (90 percent had type 1), median survival was 3.9 years [82]. The risk of early death correlated with plasmalogen levels (ie, patients with very low plasmalogen levels had shorter survival compared with those whose plasmalogen levels were only modestly decreased).

Refsum disease — Refsum disease (MIM #266500) is characterized by progressive vision loss and peripheral neuropathy. A major difference from other peroxisomal disorders is that this disorder responds to dietary treatment.

Genetics — Refsum disease is an autosomal recessive disorder. In most instances, Refsum disease is caused by variants in the gene PHYH, which encodes the enzyme phytanoyl-CoA hydroxylase [91-93]. A minority of individuals with Refsum disease have variants in the PEX7 gene [83].

Clinical features — Patients with adult Refsum disease usually present in adolescence or early adulthood. Clinical features include [49,94]:

Progressive vision loss – Impaired night vision is often the first symptom, followed by progressive loss of visual acuity due to retinitis pigmentosa (see "Retinitis pigmentosa: Clinical presentation and diagnosis")

Anosmia

Sensorineural hearing loss

Peripheral neuropathy

Ataxia

Ichthyosis

Cardiac arrhythmias (typically with onset 10 to 15 years after initial presentation)

The constellation of symptoms is variable; few patients have all these findings [94,95]. Cognitive function is typically normal.

The clinical course is variable. Exacerbations of neurologic symptoms may occur with acute illness, fasting, rapid weight loss, surgery, or pregnancy [49].

Brain MRI abnormalities in patients with Refsum disease have been described but no clear pattern can be distinguished [96,97].

Diagnosis — When Refsum disease is suspected clinically, we suggest initial testing with plasma phytanic acid level. Values in individuals with Refsum disease are typically >200 micromol/L, whereas normal values are usually <15 micromol/L [94,98].

The combination of characteristic clinical features and elevated plasma phytanic acid level is sufficient to establish a preliminary diagnosis of Refsum disease. The diagnosis is confirmed with genetic testing [99]. Genetic testing ensures certainty of the diagnosis and facilitates genetic counseling.

Additional confirmatory testing may include a functional assay of PHYH activity in fibroblasts [99]. This is most helpful when genetic testing identifies a VUS. Functional assays are performed in this setting to evaluate the biochemical significance of the variant.

Treatment — The mainstay of treatment is dietary restriction to eliminate phytol-containing foods. Patients with acute severe neurologic symptoms due to elevated phytanic acid levels may require plasmapheresis.

Dietary restriction of phytanic acid intake – Foods to avoid include [49,94]:

Meat or fats from cows and other ruminant animals

Baked goods containing animal fats

Dairy products

Most green vegetables are allowed since they contain low levels of free phytol [100].

The goal of dietary management is to reduce intake of phytanic acid to <10 mg daily. Care should be taken to avoid rapid weight loss or fasting, since this can trigger exacerbations of neurologic symptoms [101].

Limited data suggest that strict reduction in dietary phytanic acid intake may improve peripheral neuropathy and ataxia [102]. In a series of 13 adult patients with Refsum disease treated with dietary therapy for ≥10 years, phytanic acid levels declined by almost 90 percent [101]. None of the participants required admission for acute symptoms of Refsum disease and/or treatment with plasmapheresis.

Plasmapheresis – For patients with severe acute neurologic symptoms, plasmapheresis can be used to rapidly lower the phytanic acid level [102,103]. Serial treatments may be necessary in some cases. Plasmapheresis efficiently removes phytanic acid associated with lipoproteins but does not efficiently deplete phytanic acid in adipose and neural tissue. Thus, it does not completely reverse neurologic abnormalities.

X-linked adrenoleukodystrophy — The features of X-linked adrenoleukodystrophy are summarized in the table (table 3) and discussed in detail separately. (See "Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy", section on 'Clinical features'.)

Primary hyperoxaluria type 1 — The primary hyperoxalurias (PH) are a group of rare inborn errors of glyoxylate metabolism resulting in enhanced production of oxalate. Type 1 PH is the most severe form. Affected patients present in infancy or early childhood with symptoms related to nephrocalcinosis, kidney stones, and chronic kidney disease. Type 1 PH is discussed in detail separately. (See "Primary hyperoxaluria", section on 'Primary hyperoxaluria type 1'.)

Other disorders

ACOX2 deficiency – ACOX2 deficiency is a newly identified defect that has been described in a few case reports and small case series [104-106]. This defect is restricted to the involvement of peroxisomes in bile acid synthesis. It has been described in only seven patients, all of whom had elevated transaminases and elevated levels of bile acid intermediates with otherwise normal peroxisomal parameters [104-106]. Clinical manifestations in these patients included chronic fatigue, growth failure, developmental delay/cognitive impairment, congenital heart disease, ataxia, and cirrhosis. Two patients were asymptomatic.

AMACR deficiency – There are few reported cases of AMACR (2-methylacyl-CoA racemase) deficiency in literature [107]. In the available reports, the onset of disease was most commonly in the fifth or sixth decade of life, though there have been a few cases of childhood or neonatal onset, including one case of fulminant neonatal liver disease [107,108]. Adult-onset disease generally consists of peripheral neuropathy, retinitis pigmentosa, recurrent seizures, and cognitive decline [107,109-115].

BAAT deficiency – BAAT (bile acid-CoA: amino acid N-acyltransferase) deficiency has been reported in two case series [116,117]. Clinical features of affected patients included fat malabsorption, growth failure, neonatal cholestasis, and liver disease (including fulminant liver failure in one patient).

ACOX1 gain-of-function (Mitchell syndrome) – Mitchell syndrome (MIM #618960) is a rare disorder caused by a single de novo ACOX1 variant ("p.N237S") that results in upregulation of the gene (ie, increased ACOX1 protein levels and function), leading to oxidative cellular injury in neuronal tissue [118]. VLCFA levels are normal. The phenotype partially mimics a central nervous system (CNS) inflammatory condition [119]. In the available case reports, which included a total of nine patients, clinical manifestations included progressive gait instability due to polyneuropathy, white matter changes on brain MRI, ocular keratitis, and skin rashes [118-120]. The disease course is described as relapsing and then progressive. Approximately half of the affected patients died in childhood.

This disorder is distinct from ACOX1 deficiency, which has a phenotype that is indistinguishable from ZSD. (See 'ACOX1 and DBP deficiencies' above.)

FAR1 gain-of-function (CSPSD disorder) – Cataracts, spastic paraparesis, and speech delay (CSPSD) disorder (MIM #619338) is a rare autosomal dominant disorder caused by three de novo missense variants in the FAR1 gene affecting the same amino acid residue (p.480Arg) [121]. The defect results in increased FAR1 levels, plasmalogen accumulation, and cellular lipidome remodeling. The clinical features of CSPSD disorder were described in a case series of 12 individuals who presented in childhood with cataracts and cerebral palsy.

CSPSD is distinct from FAR1 deficiency, which causes RCDP type 4. However, interestingly, the phenotype of CSPSD partially overlap with that of the autosomal recessive RCDPs (both cause cataracts, developmental delay, and seizures). Notably, rhizomelia is not a feature of CSPSD. (See 'RCDP spectrum disorders' above.)

Other rare disorders – Other rare disorders that have been described in single case reports include:

ACBD5 (acyl-CoA-binding domain type 5) deficiency [122]

Glycolate oxidase deficiency [123,124]

PMP70 (peroxisomal membrane protein 70) deficiency caused by a mutation in the ABCD3 gene [125]

SCPX (sterol carrier protein X) deficiency [126]

Rare disorders of peroxisome division (caused by mutations in genes encoding proteins involved in peroxisome division [eg, PEX11 beta, DLP1/DNML1, MFF, GDAP1]) [3]

SUMMARY AND RECOMMENDATIONS

Physiology – Peroxisomes are subcellular organelles that are present in all cells except erythrocytes. They host numerous catabolic and anabolic pathways that are essential to normal cellular metabolism. Peroxisomal disorders are a heterogeneous group of inborn errors of metabolism that result in impairment of peroxisome function. In most cases, this results in neurologic dysfunction of varying extent. (See 'Pathophysiology' above and 'Neuropathology' above.)

Peroxisomal disorders can be caused by defects in the biogenesis of peroxisomes or by deficiencies of individual peroxisomal enzymes or proteins (table 1). A rare third category is disorders of peroxisome division. (See 'Classification by mechanism' above.)

Clinical classification – Clinically, the peroxisomal disorders can be subdivided into six main groups, including (table 2) (see 'Clinical classification' above):

Cerebrohepatorenal syndromes – This category includes disorders that are characterized by variable degrees of liver and kidney involvement in conjunction with neurologic abnormalities, vision and hearing impairment, and craniofacial dysmorphisms. These include:

-Zellweger spectrum disorders (see 'Zellweger spectrum disorders' above)

-Acyl CoA oxidase-1 (ACOX1) deficiency (see 'ACOX1 and DBP deficiencies' above)

-D-bifunctional protein (DBP) deficiency (see 'ACOX1 and DBP deficiencies' above)

Rhizomelic chondrodysplasias – This category includes rhizomelic chondrodysplasia punctata (RCDP) types 1 to 5. The unique feature that distinguishes RDCPs from other peroxisomal disorders is pronounced growth failure with shortened proximal long bones (rhizomelia). Other clinical features include developmental delay, dysmorphic facies, congenital cataracts, ichthyosis, and joint contractures. (See 'RCDP spectrum disorders' above.)

Refsum disease – Refsum disease is characterized by progressive vision loss and peripheral neuropathy. Unlike many other peroxisomal disorders, which often present in infancy or early childhood, Refsum disease typically presents in adolescence or early adulthood. Another distinction is that Refsum disease responds to dietary treatment. (See 'Refsum disease' above.)

X-linked adrenoleukodystrophy (ALD) – The clinical spectrum of X-ALD is variable, as summarized in the table (table 3) and discussed in detail separately. (See "Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy", section on 'Clinical features'.)

Primary hyperoxaluria type 1 (PH1) – PH1 is characterized by recurrent kidney stones and chronic kidney disease. It is discussed in detail separately. (See "Primary hyperoxaluria", section on 'Primary hyperoxaluria type 1'.)

Other rare disorders – The sixth category consists of a group of rare disorders with variable features. (See 'Other disorders' above.)

Clinical features – The clinical spectrum of peroxisomal disorders is broad, ranging from severe neurologic disability presenting in the neonatal period to milder disease manifesting in adulthood. Common clinical features that should prompt consideration of a peroxisomal disorder include (see 'Common clinical features' above):

Central and peripheral nervous system findings

Vision problems, retinopathy, cataracts, and other eye problems

Sensorineural hearing loss

Liver disease

Adrenal insufficiency

Skeletal abnormalities, such as shortened proximal long bones (rhizomelia) and calcific stippling on bone radiographs (chondrodysplasia punctata)

Diagnostic approach – In general, testing for peroxisomal disorders begins with measurement of biochemical markers. Testing is tailored to the specific disorder(s) suspected based upon the constellation of clinical findings (table 2) (see 'Diagnostic approach' above):

Suspected ZSD (or ACOX1 or DBP deficiency, which are clinically indistinguishable) – Initial testing consists of measuring plasma C26:0-lysophosphatidylcholine (C26:0-LPC), where available, or standard very long-chain fatty acid (VLCFA) analysis if C26:0-LPC testing is not available. (See 'Diagnosis' above.)

Suspected RCDP disorders – Initial testing consists of erythrocyte plasmalogen analysis. (See 'Diagnosis' above.)

Suspected Refsum disease – Initial testing consists of plasma phytanic acid levels. (See 'Diagnosis' above.)

Suspected X-ALD – Initial testing consists of measuring plasma C26:0-LPC, where available, or standard VLCFA analysis if C26:0-LPC testing is not available (table 3). (See "Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy", section on 'Laboratory testing'.)

Primary hyperoxaluria type 1 (PH1) – Initial testing consists of measuring urinary oxalate. (See "Primary hyperoxaluria", section on 'Metabolic testing'.)

If the initial biochemical test is abnormal, confirmatory genetic testing is generally required. Additional confirmatory testing with functional assays using fibroblasts can sometimes be useful in the diagnostic evaluation (eg, if genetic testing identifies a variant of uncertain significance).

ACKNOWLEDGMENT — 

The UpToDate editorial staff acknowledges Alan K Percy, MD, and Raphael Schiffman, MD, MHSc, FAAN, who contributed to earlier versions of this topic review.

  1. Braverman NE, Raymond GV, Rizzo WB, et al. Peroxisome biogenesis disorders in the Zellweger spectrum: An overview of current diagnosis, clinical manifestations, and treatment guidelines. Mol Genet Metab 2016; 117:313.
  2. Klouwer FC, Berendse K, Ferdinandusse S, et al. Zellweger spectrum disorders: clinical overview and management approach. Orphanet J Rare Dis 2015; 10:151.
  3. Wanders RJA, Baes M, Ribeiro D, et al. The physiological functions of human peroxisomes. Physiol Rev 2023; 103:957.
  4. Waterham HR, Ferdinandusse S, Wanders RJ. Human disorders of peroxisome metabolism and biogenesis. Biochim Biophys Acta 2016; 1863:922.
  5. Mohan S, Mayers M, Weaver M, et al. Evaluating the strength of evidence for genes implicated in peroxisomal disorders using the ClinGen clinical validity framework and providing updates to the peroxisomal disease nomenclature. Mol Genet Metab 2023; 139:107604.
  6. Baumgartner MR, Poll-The BT, Verhoeven NM, et al. Clinical approach to inherited peroxisomal disorders: a series of 27 patients. Ann Neurol 1998; 44:720.
  7. Gilles L, Adams R, Kolony E. The neurology of neonatal hereditary metabolic diseases. In: Neurology of Hereditary Metabolic Diseases of Children, 2nd ed, McGraw Hill, New York 1996.
  8. Thomas JA, Greene CL, Cohn RM. Lysosomal storage and peroxisomal disorders presenting in the newborn. In: Avery's Diseases of the Newborn, 7th ed, Taeusch HW, Ballard RA (Eds), WB Saunders, Philadelphia 1998. p.275.
  9. Wanders RJ, Waterham HR. Biochemistry of mammalian peroxisomes revisited. Annu Rev Biochem 2006; 75:295.
  10. Van Veldhoven PP. Biochemistry and genetics of inherited disorders of peroxisomal fatty acid metabolism. J Lipid Res 2010; 51:2863.
  11. Wanders RJ. Metabolic functions of peroxisomes in health and disease. Biochimie 2014; 98:36.
  12. Wanders RJ, Waterham HR, Ferdinandusse S. Metabolic Interplay between Peroxisomes and Other Subcellular Organelles Including Mitochondria and the Endoplasmic Reticulum. Front Cell Dev Biol 2015; 3:83.
  13. Crane DI. Revisiting the neuropathogenesis of Zellweger syndrome. Neurochem Int 2014; 69:1.
  14. Kassmann CM, Lappe-Siefke C, Baes M, et al. Axonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes. Nat Genet 2007; 39:969.
  15. Powers JM. Normal and defective neuronal membranes: structure and function: neuronal lesions in peroxisomal disorders. J Mol Neurosci 2001; 16:285.
  16. Volpe JJ, Adams RD. Cerebro-hepato-renal syndrome of Zellweger: an inherited disorder of neuronal migration. Acta Neuropathol 1972; 20:175.
  17. Kelley RI, Datta NS, Dobyns WB, et al. Neonatal adrenoleukodystrophy: new cases, biochemical studies, and differentiation from Zellweger and related peroxisomal polydystrophy syndromes. Am J Med Genet 1986; 23:869.
  18. Powers JM. The pathology of peroxisomal disorders with pathogenetic considerations. J Neuropathol Exp Neurol 1995; 54:710.
  19. Kaufmann WE, Theda C, Naidu S, et al. Neuronal migration abnormality in peroxisomal bifunctional enzyme defect. Ann Neurol 1996; 39:268.
  20. Dimmick JE, Applegarth DA. Pathology of peroxisomal disorders. Perspect Pediatr Pathol 1993; 17:45.
  21. Powers J. Peroxisomal diseases. In: Pediatric Neuropathology, Williams and Wilkins, Baltimore, MD 1995.
  22. YAKOVAC WC. Calcareous chondropathies in the newborn infant. AMA Arch Pathol 1954; 57:62.
  23. Griffin DE, Moser HW, Mendoza Q, et al. Identification of the inflammatory cells in the central nervous system of patients with adrenoleukodystrophy. Ann Neurol 1985; 18:660.
  24. Powers JM, Liu Y, Moser AB, Moser HW. The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules, and pathogenetic implications. J Neuropathol Exp Neurol 1992; 51:630.
  25. Powers JM, Moser HW. Peroxisomal disorders: genotype, phenotype, major neuropathologic lesions, and pathogenesis. Brain Pathol 1998; 8:101.
  26. Powers JM, DeCiero DP, Ito M, et al. Adrenomyeloneuropathy: a neuropathologic review featuring its noninflammatory myelopathy. J Neuropathol Exp Neurol 2000; 59:89.
  27. Powers JM, DeCiero DP, Cox C, et al. The dorsal root ganglia in adrenomyeloneuropathy: neuronal atrophy and abnormal mitochondria. J Neuropathol Exp Neurol 2001; 60:493.
  28. Powers JM, Pei Z, Heinzer AK, et al. Adreno-leukodystrophy: oxidative stress of mice and men. J Neuropathol Exp Neurol 2005; 64:1067.
  29. Theil AC, Schutgens RB, Wanders RJ, Heymans HS. Clinical recognition of patients affected by a peroxisomal disorder: a retrospective study in 40 patients. Eur J Pediatr 1992; 151:117.
  30. Klouwer FC, Huffnagel IC, Ferdinandusse S, et al. Clinical and Biochemical Pitfalls in the Diagnosis of Peroxisomal Disorders. Neuropediatrics 2016; 47:205.
  31. Bose M, Yergeau C, D'Souza Y, et al. Characterization of Severity in Zellweger Spectrum Disorder by Clinical Findings: A Scoping Review, Meta-Analysis and Medical Chart Review. Cells 2022; 11.
  32. De Biase I, Tortorelli S, Kratz L, et al. Laboratory diagnosis of disorders of peroxisomal biogenesis and function: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med 2020; 22:686.
  33. Ferdinandusse S, Ebberink MS, Vaz FM, et al. The important role of biochemical and functional studies in the diagnostics of peroxisomal disorders. J Inherit Metab Dis 2016; 39:531.
  34. Lledó B, Bernabeu R, Ten J, et al. Preimplantation genetic diagnosis of X-linked adrenoleukodystrophy with gender determination using multiple displacement amplification. Fertil Steril 2007; 88:1327.
  35. Johnson JM, Babul-Hirji R, Chitayat D. First-trimester increased nuchal translucency and fetal hypokinesia associated with Zellweger syndrome. Ultrasound Obstet Gynecol 2001; 17:344.
  36. Hertzberg BS, Kliewer MA, Decker M, et al. Antenatal ultrasonographic diagnosis of rhizomelic chondrodysplasia punctata. J Ultrasound Med 1999; 18:715.
  37. Ratbi I, Falkenberg KD, Sommen M, et al. Heimler Syndrome Is Caused by Hypomorphic Mutations in the Peroxisome-Biogenesis Genes PEX1 and PEX6. Am J Hum Genet 2015; 97:535.
  38. Ebberink MS, Mooijer PA, Gootjes J, et al. Genetic classification and mutational spectrum of more than 600 patients with a Zellweger syndrome spectrum disorder. Hum Mutat 2011; 32:59.
  39. Geisbrecht BV, Collins CS, Reuber BE, Gould SJ. Disruption of a PEX1-PEX6 interaction is the most common cause of the neurologic disorders Zellweger syndrome, neonatal adrenoleukodystrophy, and infantile Refsum disease. Proc Natl Acad Sci U S A 1998; 95:8630.
  40. Turner CL, Bunyan DJ, Thomas NS, et al. Zellweger syndrome resulting from maternal isodisomy of chromosome 1. Am J Med Genet A 2007; 143A:2172.
  41. Falkenberg KD, Braverman NE, Moser AB, et al. Allelic Expression Imbalance Promoting a Mutant PEX6 Allele Causes Zellweger Spectrum Disorder. Am J Hum Genet 2017; 101:965.
  42. Matsui S, Funahashi M, Honda A, Shimozawa N. Newly identified milder phenotype of peroxisome biogenesis disorder caused by mutated PEX3 gene. Brain Dev 2013; 35:842.
  43. Waterham HR, Koster J, Ebberink MS, et al. Autosomal dominant Zellweger spectrum disorder caused by de novo variants in PEX14 gene. Genet Med 2023; 25:100944.
  44. Preuss N, Brosius U, Biermanns M, et al. PEX1 mutations in complementation group 1 of Zellweger spectrum patients correlate with severity of disease. Pediatr Res 2002; 51:706.
  45. Collins CS, Gould SJ. Identification of a common PEX1 mutation in Zellweger syndrome. Hum Mutat 1999; 14:45.
  46. Maxwell MA, Nelson PV, Chin SJ, et al. A common PEX1 frameshift mutation in patients with disorders of peroxisome biogenesis correlates with the severe Zellweger syndrome phenotype. Hum Genet 1999; 105:38.
  47. Smith DW, Opitz JM, Inhorn SL. A syndrome of multiple developmental defects including polycystic kidneys and intrahepatic biliary dysgenesis in 2 siblings. J Pediatr 1965; 67:617.
  48. Passarge E, McAdams AJ. Cerebro-hepato-renal syndrome. A newly recognized hereditary disorder of multiple congenital defects, including sudanophilic leukodystrophy, cirrhosis of the liver, and polycystic kidneys. J Pediatr 1967; 71:691.
  49. Percy AK, Rutledge SL. Adrenoleukodystrophy and related disorders. Ment Retard Dev Disabil Res Rev 2001; 7:179.
  50. Volpe JJ. Degenerative diseases of the newborn. In: Neurology of the Newborn, 4th ed, WB Saunders, Philadelphia 2001. p.599.
  51. Shimozawa N. Molecular and clinical aspects of peroxisomal diseases. J Inherit Metab Dis 2007; 30:193.
  52. Régal L, Ebberink MS, Goemans N, et al. Mutations in PEX10 are a cause of autosomal recessive ataxia. Ann Neurol 2010; 68:259.
  53. Sevin C, Ferdinandusse S, Waterham HR, et al. Autosomal recessive cerebellar ataxia caused by mutations in the PEX2 gene. Orphanet J Rare Dis 2011; 6:8.
  54. Berendse K, Engelen M, Linthorst GE, et al. High prevalence of primary adrenal insufficiency in Zellweger spectrum disorders. Orphanet J Rare Dis 2014; 9:133.
  55. van der Knaap MS, Wassmer E, Wolf NI, et al. MRI as diagnostic tool in early-onset peroxisomal disorders. Neurology 2012; 78:1304.
  56. Barkovich AJ, Peck WW. MR of Zellweger syndrome. AJNR Am J Neuroradiol 1997; 18:1163.
  57. Barth PG, Gootjes J, Bode H, et al. Late onset white matter disease in peroxisome biogenesis disorder. Neurology 2001; 57:1949.
  58. Barth PG, Majoie CB, Gootjes J, et al. Neuroimaging of peroxisome biogenesis disorders (Zellweger spectrum) with prolonged survival. Neurology 2004; 62:439.
  59. Poll-The BT, Gärtner J. Clinical diagnosis, biochemical findings and MRI spectrum of peroxisomal disorders. Biochim Biophys Acta 2012; 1822:1421.
  60. Klouwer FCC, Ferdinandusse S, van Lenthe H, et al. Evaluation of C26:0-lysophosphatidylcholine and C26:0-carnitine as diagnostic markers for Zellweger spectrum disorders. J Inherit Metab Dis 2017; 40:875.
  61. Rosewich H, Waterham HR, Wanders RJ, et al. Pitfall in metabolic screening in a patient with fatal peroxisomal beta-oxidation defect. Neuropediatrics 2006; 37:95.
  62. Pierce SB, Walsh T, Chisholm KM, et al. Mutations in the DBP-deficiency protein HSD17B4 cause ovarian dysgenesis, hearing loss, and ataxia of Perrault Syndrome. Am J Hum Genet 2010; 87:282.
  63. McMillan HJ, Worthylake T, Schwartzentruber J, et al. Specific combination of compound heterozygous mutations in 17β-hydroxysteroid dehydrogenase type 4 (HSD17B4) defines a new subtype of D-bifunctional protein deficiency. Orphanet J Rare Dis 2012; 7:90.
  64. Lines MA, Jobling R, Brady L, et al. Peroxisomal D-bifunctional protein deficiency: three adults diagnosed by whole-exome sequencing. Neurology 2014; 82:963.
  65. Berendse K, Engelen M, Ferdinandusse S, et al. Zellweger spectrum disorders: clinical manifestations in patients surviving into adulthood. J Inherit Metab Dis 2016; 39:93.
  66. Lam C, Wong D, Cederbaum S, et al. Peanut consumption increases levels of plasma very long chain fatty acids in humans. Mol Genet Metab 2012; 107:620.
  67. Theda C, Woody RC, Naidu S, et al. Increased very long chain fatty acids in patients on a ketogenic diet: a cause of diagnostic confusion. J Pediatr 1993; 122:724.
  68. Martinez M. Restoring the DHA levels in the brains of Zellweger patients. J Mol Neurosci 2001; 16:309.
  69. Paker AM, Sunness JS, Brereton NH, et al. Docosahexaenoic acid therapy in peroxisomal diseases: results of a double-blind, randomized trial. Neurology 2010; 75:826.
  70. Berendse K, Klouwer FC, Koot BG, et al. Cholic acid therapy in Zellweger spectrum disorders. J Inherit Metab Dis 2016; 39:859.
  71. Klouwer FCC, Koot BGP, Berendse K, et al. The cholic acid extension study in Zellweger spectrum disorders: Results and implications for therapy. J Inherit Metab Dis 2019; 42:303.
  72. CHOLBAM prescribing information, available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205750lbl.pdf (Accessed on March 20, 2015).
  73. Kolbam EMA withdrawal https://www.ema.europa.eu/en/medicines/human/EPAR/kolbam (Accessed on July 17, 2020).
  74. Ferdinandusse S, Denis S, Hogenhout EM, et al. Clinical, biochemical, and mutational spectrum of peroxisomal acyl-coenzyme A oxidase deficiency. Hum Mutat 2007; 28:904.
  75. Ferdinandusse S, Denis S, Mooyer PA, et al. Clinical and biochemical spectrum of D-bifunctional protein deficiency. Ann Neurol 2006; 59:92.
  76. Braverman N, Chen L, Lin P, et al. Mutation analysis of PEX7 in 60 probands with rhizomelic chondrodysplasia punctata and functional correlations of genotype with phenotype. Hum Mutat 2002; 20:284.
  77. Motley AM, Hettema EH, Hogenhout EM, et al. Rhizomelic chondrodysplasia punctata is a peroxisomal protein targeting disease caused by a non-functional PTS2 receptor. Nat Genet 1997; 15:377.
  78. Braverman N, Steel G, Obie C, et al. Human PEX7 encodes the peroxisomal PTS2 receptor and is responsible for rhizomelic chondrodysplasia punctata. Nat Genet 1997; 15:369.
  79. Purdue PE, Zhang JW, Skoneczny M, Lazarow PB. Rhizomelic chondrodysplasia punctata is caused by deficiency of human PEX7, a homologue of the yeast PTS2 receptor. Nat Genet 1997; 15:381.
  80. Ofman R, Hettema EH, Hogenhout EM, et al. Acyl-CoA:dihydroxyacetonephosphate acyltransferase: cloning of the human cDNA and resolution of the molecular basis in rhizomelic chondrodysplasia punctata type 2. Hum Mol Genet 1998; 7:847.
  81. Motley AM, Brites P, Gerez L, et al. Mutational spectrum in the PEX7 gene and functional analysis of mutant alleles in 78 patients with rhizomelic chondrodysplasia punctata type 1. Am J Hum Genet 2002; 70:612.
  82. Duker AL, Niiler T, Kinderman D, et al. Rhizomelic chondrodysplasia punctata morbidity and mortality, an update. Am J Med Genet A 2020; 182:579.
  83. van den Brink DM, Brites P, Haasjes J, et al. Identification of PEX7 as the second gene involved in Refsum disease. Am J Hum Genet 2003; 72:471.
  84. Buchert R, Tawamie H, Smith C, et al. A peroxisomal disorder of severe intellectual disability, epilepsy, and cataracts due to fatty acyl-CoA reductase 1 deficiency. Am J Hum Genet 2014; 95:602.
  85. Barøy T, Koster J, Strømme P, et al. A novel type of rhizomelic chondrodysplasia punctata, RCDP5, is caused by loss of the PEX5 long isoform. Hum Mol Genet 2015; 24:5845.
  86. Fallatah W, Schouten M, Yergeau C, et al. Clinical, biochemical, and molecular characterization of mild (nonclassic) rhizomelic chondrodysplasia punctata. J Inherit Metab Dis 2021; 44:1021.
  87. Viola A, Confort-Gouny S, Ranjeva JP, et al. MR imaging and MR spectroscopy in rhizomelic chondrodysplasia punctata. AJNR Am J Neuroradiol 2002; 23:480.
  88. Goh S. Neuroimaging features in a neonate with rhizomelic chondrodysplasia punctata. Pediatr Neurol 2007; 37:382.
  89. Bams-Mengerink AM, Majoie CB, Duran M, et al. MRI of the brain and cervical spinal cord in rhizomelic chondrodysplasia punctata. Neurology 2006; 66:798.
  90. Smeitink JA, Beemer FA, Espeel M, et al. Bone dysplasia associated with phytanic acid accumulation and deficient plasmalogen synthesis: a peroxisomal entity amenable to plasmapheresis. J Inherit Metab Dis 1992; 15:377.
  91. Jansen GA, Ofman R, Ferdinandusse S, et al. Refsum disease is caused by mutations in the phytanoyl-CoA hydroxylase gene. Nat Genet 1997; 17:190.
  92. Mihalik SJ, Morrell JC, Kim D, et al. Identification of PAHX, a Refsum disease gene. Nat Genet 1997; 17:185.
  93. Jansen GA, Hogenhout EM, Ferdinandusse S, et al. Human phytanoyl-CoA hydroxylase: resolution of the gene structure and the molecular basis of Refsum's disease. Hum Mol Genet 2000; 9:1195.
  94. Wierzbicki AS, Lloyd MD, Schofield CJ, et al. Refsum's disease: a peroxisomal disorder affecting phytanic acid alpha-oxidation. J Neurochem 2002; 80:727.
  95. Wierzbicki AS, Mitchell J, Lambert-Hammill M, et al. Identification of genetic heterogeneity in Refsum's disease. Eur J Hum Genet 2000; 8:649.
  96. Hamel C. Retinitis pigmentosa. Orphanet J Rare Dis 2006; 1:40.
  97. Bompaire F, Marcaud V, Trionnaire EL, et al. Refsum Disease Presenting with a Late-Onset Leukodystrophy. JIMD Rep 2015; 19:7.
  98. Verhoeven NM, Kulik W, van den Heuvel CM, Jakobs C. Pre- and postnatal diagnosis of peroxisomal disorders using stable-isotope dilution gas chromatography--mass spectrometry. J Inherit Metab Dis 1995; 18 Suppl 1:45.
  99. Jansen GA, Waterham HR, Wanders RJ. Molecular basis of Refsum disease: sequence variations in phytanoyl-CoA hydroxylase (PHYH) and the PTS2 receptor (PEX7). Hum Mutat 2004; 23:209.
  100. Brown PJ, Mei G, Gibberd FB, et al. Diet and Refsum's disease: The determination of phytanic acid and phytol in certain foods and the application of this knowledge to the choice of suitable convenience foods for patients with Refsum's disease. J Hum Nutr Diet 1993; 6:295.
  101. Baldwin EJ, Gibberd FB, Harley C, et al. The effectiveness of long-term dietary therapy in the treatment of adult Refsum disease. J Neurol Neurosurg Psychiatry 2010; 81:954.
  102. Hungerbühler JP, Meier C, Rousselle L, et al. Refsum's disease: management by diet and plasmapheresis. Eur Neurol 1985; 24:153.
  103. Harari D, Gibberd FB, Dick JP, Sidey MC. Plasma exchange in the treatment of Refsum's disease (heredopathia atactica polyneuritiformis). J Neurol Neurosurg Psychiatry 1991; 54:614.
  104. Vilarinho S, Sari S, Mazzacuva F, et al. ACOX2 deficiency: A disorder of bile acid synthesis with transaminase elevation, liver fibrosis, ataxia, and cognitive impairment. Proc Natl Acad Sci U S A 2016; 113:11289.
  105. Monte MJ, Alonso-Peña M, Briz O, et al. ACOX2 deficiency: An inborn error of bile acid synthesis identified in an adolescent with persistent hypertransaminasemia. J Hepatol 2017; 66:581.
  106. Alonso-Peña M, Espinosa-Escudero R, Herraez E, et al. Beneficial effect of ursodeoxycholic acid in patients with acyl-CoA oxidase 2 (ACOX2) deficiency-associated hypertransaminasemia. Hepatology 2022; 76:1259.
  107. Tanti MJ, Maguire MJ, Warren DJ, Bamford J. Late onset AMACR deficiency with metabolic stroke-like episodes and seizures. BMJ Case Rep 2022; 15.
  108. Setchell KD, Heubi JE, Bove KE, et al. Liver disease caused by failure to racemize trihydroxycholestanoic acid: gene mutation and effect of bile acid therapy. Gastroenterology 2003; 124:217.
  109. Ferdinandusse S, Denis S, Clayton PT, et al. Mutations in the gene encoding peroxisomal alpha-methylacyl-CoA racemase cause adult-onset sensory motor neuropathy. Nat Genet 2000; 24:188.
  110. Clarke CE, Alger S, Preece MA, et al. Tremor and deep white matter changes in alpha-methylacyl-CoA racemase deficiency. Neurology 2004; 63:188.
  111. Thompson SA, Calvin J, Hogg S, et al. Relapsing encephalopathy in a patient with alpha-methylacyl-CoA racemase deficiency. J Neurol Neurosurg Psychiatry 2008; 79:448.
  112. Kapina V, Sedel F, Truffert A, et al. Relapsing rhabdomyolysis due to peroxisomal alpha-methylacyl-coa racemase deficiency. Neurology 2010; 75:1300.
  113. Smith EH, Gavrilov DK, Oglesbee D, et al. An adult onset case of alpha-methyl-acyl-CoA racemase deficiency. J Inherit Metab Dis 2010; 33 Suppl 3:S349.
  114. Dick D, Horvath R, Chinnery PF. AMACR mutations cause late-onset autosomal recessive cerebellar ataxia. Neurology 2011; 76:1768.
  115. Stewart MW, Vavra MW, Whaley NR. FUNDUS FINDINGS IN A PATIENT WITH α-METHLYACYL-COA RACEMASE DEFICIENCY. Retin Cases Brief Rep 2011; 5:262.
  116. Heubi JE, Setchell KD, Bove KE. Inborn errors of bile acid metabolism. Semin Liver Dis 2007; 27:282.
  117. Carlton VE, Harris BZ, Puffenberger EG, et al. Complex inheritance of familial hypercholanemia with associated mutations in TJP2 and BAAT. Nat Genet 2003; 34:91.
  118. Chung HL, Wangler MF, Marcogliese PC, et al. Loss- or Gain-of-Function Mutations in ACOX1 Cause Axonal Loss via Different Mechanisms. Neuron 2020; 106:589.
  119. Thiels C, Lücke T, Rothoeft T, et al. ACOX1 Gain-of-Function Variant in Two German Pediatric Patients, in One Case Mimicking Autoimmune Inflammatory Disease. Neuropediatrics 2024; 55:140.
  120. Filippi C, Brunetti S, Plumari M, et al. ACOX1 gain-of-function variation in a 10-years-old patient responsive to immunomodulating therapy. Am J Med Genet A 2024; 194:e63796.
  121. Ferdinandusse S, McWalter K, Te Brinke H, et al. An autosomal dominant neurological disorder caused by de novo variants in FAR1 resulting in uncontrolled synthesis of ether lipids. Genet Med 2021; 23:740.
  122. Ferdinandusse S, Falkenberg KD, Koster J, et al. ACBD5 deficiency causes a defect in peroxisomal very long-chain fatty acid metabolism. J Med Genet 2017; 54:330.
  123. Frishberg Y, Zeharia A, Lyakhovetsky R, et al. Mutations in HAO1 encoding glycolate oxidase cause isolated glycolic aciduria. J Med Genet 2014; 51:526.
  124. Clifford-Mobley O, Rumsby G, Kanodia S, et al. Glycolate oxidase deficiency in a patient with congenital hyperinsulinism and unexplained hyperoxaluria. Pediatr Nephrol 2017; 32:2159.
  125. Ferdinandusse S, Jimenez-Sanchez G, Koster J, et al. A novel bile acid biosynthesis defect due to a deficiency of peroxisomal ABCD3. Hum Mol Genet 2015; 24:361.
  126. Ferdinandusse S, Kostopoulos P, Denis S, et al. Mutations in the gene encoding peroxisomal sterol carrier protein X (SCPx) cause leukencephalopathy with dystonia and motor neuropathy. Am J Hum Genet 2006; 78:1046.
Topic 6147 Version 28.0

References